Century Therapeutics Inc. (IPSC)
Company Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.
The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma.
Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Country | United States |
IPO Date | Jun 18, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 140 |
CEO | Dr. Morgan Conn Ph.D. |
Contact Details
Address: 3675 Market Street Philadelphia, Pennsylvania United States | |
Website | https://www.centurytx.com |
Stock Details
Ticker Symbol | IPSC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001850119 |
CUSIP Number | 15673T100 |
ISIN Number | US15673T1007 |
Employer ID | 84-2040295 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Morgan Conn Ph.D. | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 22, 2025 | ARS | Filing |
Apr 22, 2025 | DEFA14A | Filing |
Apr 22, 2025 | DEF 14A | Filing |
Mar 20, 2025 | S-8 | Filing |
Mar 19, 2025 | 8-K | Current Report |
Mar 19, 2025 | 10-K | Annual Report |
Mar 12, 2025 | 4 | Filing |
Mar 12, 2025 | 4 | Filing |
Mar 12, 2025 | 4 | Filing |
Mar 12, 2025 | 4 | Filing |